^
    Back
    Association details:
    Biomarker:BCL2 overexpression + MYC overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Blood Adv
    Title:

    Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

    Published date:
    05/11/2023
    Excerpt:
    EFS was superior with ibrutinib plus R-CHOP compared with R-CHOP alone in patients with high BCL2/MYC coexpression...EFS and OS showed clinically meaningful improvement with ibrutinib plus R-CHOP over R-CHOP alone in patients aged <60 years with high BCL2/MYC coexpression....Consequently, high BCL2/MYC coexpression identified a subset of non-GCB DLBCL that may be preferentially responsive to ibrutinib...
    Secondary therapy:
    R-CHOP
    DOI:
    10.1182/bloodadvances.2022009389
    Trial ID:
    PHOENIX